mobile version

Pleural Mesothelioma/Peritoneal
Mesothelioma Symptoms
  and Diagnosis
Mesothelioma Staging
Treatment Options
Alimta Medication
Mesothelioma Clinical Trials
Types of Lung Cancer
Lung Cancer Symptoms
Lung Cancer Staging
Lung Cancer Treatment Options
Locations By State
Questions and Information
 From Your Doctor
VA Hospitals, Clinics, & Centers
Veteran Service Officers
History, Ships, & Shipyards
Mesothelioma News
Patient Stories
Web Resources
Patient Handout
Glossary of Terms
Contact us

 Search for information:
any search words
all search words

Click Here for a Free
Information Packet

Please call

We will gladly answer your
questions and send a free
packet with additional
information on:

  • New treatment options
  • New clinical trials
  • Doctors
  • Hazardous jobs and products
  • Veteran's Resources
  • Financial Assistance




Lung Cancer and Mesothelioma Information



Mesothelioma and Lung Cancer News - Return to Menu

Gene Signature Predicts Recurrence in Non–Small Cell Lung Cancer

According to an article recently published in the New England Journal of Medicine, a gene expression profile, referred to as the lung metagene model, can help predict which patients with early non–small cell lung cancer are at a high risk for recurrence. Ultimately, these patients may benefit from additional treatment or more aggressive therapies than those at a lower risk for a recurrence.

Lung cancer remains the leading cause of cancer-related deaths in the world. Non–small cell lung cancer (NSCLC) is the most common type of lung cancer; “non–small cell” refers to the type of cell within the lung where the cancer originated. Early NSCLC refers to cancer that has not spread to distant sites in the body. Patients with early NSCLC have the best chances for long-term survival; however, a significant portion of these patients still experience a recurrence and succumb to their disease.

Researchers have been trying to identify specific patterns of gene expressions that may reveal characteristics of cancer.

Researchers from several institutions in the United States recently identified expressions of genes that predicted the risk of a cancer recurrence among 89 patients with early-stage NSCLC. To further validate these findings, the researchers evaluated the identified gene expression profile among patients with NSCLC who were involved in previous trials, the American College of Surgeons Oncology Group (ACOSOG) Z0030 study and the Cancer and Leukemia Group (CALGB) 9761 study.

The gene expression model identified, referred to as the lung metagene model, accurately predicted 72% of patients who experienced a recurrence in the ACOSOG Z0030 study, and 79% of patients who experienced a recurrence in the CALGB 9761 study.
Among patients with stage IA NSCLC, the earliest stage of the disease, the lung metagene model helped identify which patients had less than a 10% chance of survival at five years.
The researchers concluded that the lung metagene model provides significant improvement over standard clinical classifications of patients with early lung cancer when determining their risk of a recurrence. Large clinical trials further evaluating the lung metagene model have begun.

Patients diagnosed with early NSCLC may wish to speak with their physician regarding their individual risks and benefits of participating in a clinical trial further evaluating the lung metagene model or other models evaluating gene expression. Findings may help individualize their treatment.

Reference: Potti A, Mukherjee S, Petersen R, et al. A Genomic Strategy to Refine Prognosis in Early-Stage Non–SmallCell Lung Cancer. New England Journal of Medicine. 2006;355:570-580.

Related News: Molecular Profiles Help Predict Prognosis in Lung Cancer (3/15/2006)

Molecular Profiles Help Predict Prognosis in Lung Cancer

According to an article recently published in the journal Cancer Cell, molecular profiles from tissue of lung cancer can help predict prognosis, even among those with the earliest stages of lung cancer. Patients with a poor prognosis according to these results may benefit from additional therapy.

Lung cancer remains the leading cause of cancer-related deaths in the US. In fact, lung cancer is responsible for more deaths than the following three leading causes of cancer-related deaths combined: breast cancer, lung cancer, and colon cancer.

Non-small cell lung cancer (NSCLC) accounts for approximately 75%-80% of all lung cancers. “Non-small cell” refers to the type of cell within the lung where the cancer originated.

Staging of lung cancer determines of the extent of spread of the cancer. Accuracy in staging is crucial since treatment options and prognosis are primarily determined by stage.

Currently, the stage of NSCLC is typically defined by the size of the cancer and by areas within the body that the cancer has invaded. However, since survival rates among patients with the same stage of NSCLC vary widely, researchers continue to evaluate other prognostic factors that may improve staging accuracy.

Researchers from several medical institutions recently conducted a clinical study to evaluate molecular profiles referred to as microRNAs (miRNAs) and their potential to predict outcomes in patients with adenocarcinoma of the lung (a type of NSCLC).

This study included samples from 104 patients diagnosed with NSCLC. The researchers compared cancerous lung tissue to healthy lung tissue of the same patient.

The researchers identified two miRNAs, referred to as has-mir-155 and has-let-7a-2, that were associated with survival of patients.

Patients with high levels of has-mir-155 and/or low levels of has-let-7a-2 had significantly poorer survival than their counterparts. All clinical and molecular factors taken together, including stage, high levels of has-mir-155, and/or low levels of has-let-7a-2 were the most significant factors for a poor outcome.

The researchers concluded that these two miRNAs may provide value in individualizing treatment for patients with NSCLC since they appear highly predictive of outcomes for patients with this disease. Further study evaluating has-mir-155 and has-let-71-2 levels are warranted.

Reference: Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA Molecular Profiles in Lung Cancer Diagnosis and Prognosis. Cancer Cell. 2006; 9: 189-198. Continues Development of Comprehensive Mesothelioma Portal

(PRLEAP.COM) Denver, CO July 13, 2007 — Your resource on the web for legal issues that affect contemporary America,, is pleased to continue bringing readers up-to-date on the news, research and legal developments about mesothelioma. Mesothelioma is a rare and severe type of lung cancer that is almost always caused by exposure to asbestos, a once-popular building material that doctors now know is a carcinogen. Visitors to’s mesothelioma lawyer portal may browse continually-updated news feeds, original articles, encyclopedia entries, a glossary of mesothelioma-related terms and an Asbestos & Mesothelioma blog, where users can read and comment on the latest news related to these important topics.

Thousands of Americans, mostly men, were exposed to asbestos through their jobs in the first half of the 20th century, when the material was widely mined and used in building insulation, shipyards, brake pads and other industrial applications. Decades later, many of these workers discovered too late that their work with asbestos led to developing mesothelioma, a crippling type of lung cancer that attacks the lining of the lung. Others may have been exposed more recently, due to illegal and unsafe practices at modern work sites, disaster relief work near buildings that contain asbestos, or work in the few industries that still use asbestos, despite decades of evidence that it causes serious cancers. Unlike most lung cancers, mesothelioma is not caused by smoking, according to the National Cancer Institute; the Institute reports that 80 percent of mesothelioma patients had known asbestos exposure earlier in life. Mesothelioma can kill quickly; on average, doctors give patients six months to a year to live after their diagnosis. With this in mind, continues to provide factual information, news and links to more information for mesothelioma patients and their families through its mesothelioma and asbestos internet portal. strives to bring its readers complete, up-to-date information on legal issues that affect ordinary Americans. In addition to the mesothelioma resources, offers comprehensive sites with information concerning brain injury litigation, auto accident lawsuits, diabetes drug Avandia attorneys and peanut butter recall lawyers. These are in addition to general resources maintains on possible unsafe drugs, medical malpractice cases, and defective consumer products and foods. All of these sites, and others at, combine easy-to-understand information facts with the latest news, government information, jury verdicts and settlements, as well as links to more information specific to each legal issue. And for those who are ready to seek out a mesothelioma attorney or other type of experienced lawyer can find one in their areas using’s free attorney search service. is a free public service brought to you by Legal WebTV Network, LLC, a Limited Liability Corporation created by a group of the nation’s most highly respected law firms: Anapol Schwartz; Brent Coon and Associates; Burg Simpson; Cohen, Placitella and Roth; James F. Humphreys and Associates; Lopez Hodes; and Thornton and Naumes. For more information on the accomplishments and track records of’s respected sponsoring law firms and to get in touch with attorneys, visit at

To Obtain the Best Treatment Info & Financial Assistance contact us for a FREE INFORMATION PACKET which includes:

Doctors & Cancer Hospitals
Clinical Trials
Hazardous Jobs/ Products
New Treatment Options
Veteran's Resources
Financial Assistance

Fill out the form below or call 1-800-400-1805.

Use the "tab" key to move to the next field, not enter.

First Name
Last Name



Have you or a loved one been diagnosed or have:

Yes   No
Lung Cancer:

Yes   No
Had a biopsy?:

Yes   No
Did you or your loved one work around asbestos?:
Yes   No

Comment /
Info Request

Please just hit the order button once, then wait for the form to be sent


Site Map | Mesothelioma | Alimta | Lung Cancer | Non-small cell lung cancer | Small cell lung cancer | Asbestos Lung Cancer | Lung Cancer Symptoms | Mesothelioma News | Mesothelioma Symptoms | Pleural Mesothelioma | Symptoms | Breaking News | Patient Handout | Treatment | Mesothelioma Patients | Mesothelioma Causes | Mesothelioma Climical Trials | Mesothelioma treatment | Veteran's Resources | Mesothelioma Treatments